Genen­tech can­cer R&D vet Raphaël Rousseau jumps ship, joins Grit­stone

When you’re look­ing to break new ground and make a rep­u­ta­tion for your­self in can­cer R&D, one of the best places to raid tal­ent is the leg­endary biotech Genen­tech. And the per­son­al­ized can­cer vac­cine play­er Grit­stone On­col­o­gy helped prove that point again to­day with the re­cruit­ment of Genen­tech vet and long­time can­cer re­searcher Raphaël F. Rousseau as its new chief med­ical of­fi­cer.

Rousseau’s long re­sume in­cludes a stint as glob­al fran­chise head for pe­di­atrics in Genen­tech’s Prod­uct De­vel­op­ment On­col­o­gy di­vi­sion. He “man­aged a clin­i­cal team of physi­cians and sci­en­tists across sites as well as a cross-func­tion­al de­vel­op­ment and study man­age­ment team of more than 60 peo­ple across sev­er­al key func­tions, in­clud­ing clin­i­cal sci­ence, safe­ty, reg­u­la­to­ry, re­search, bio­mark­ers, clin­i­cal phar­ma­col­o­gy and op­er­a­tions,” adds his short-form bi­og­ra­phers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER